Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

SIMPLE SUMMARY: Mutations of the BRAF oncogene are reported in tumors of patients with non-small-cell lung cancer in 2–4% of cases (about half of them are V600E mutation). Dabrafenib plus trametinib combination is approved in Europe for BRAF V600E-mutant metastatic non-small-cell lung cancer. Howeve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Auliac, Jean-Bernard, Bayle, Sophie, Do, Pascal, Le Garff, Gwenaëlle, Roa, Magali, Falchero, Lionel, Huchot, Eric, Quéré, Gilles, Jeannin, Gaëlle, Métivier, Anne-Cécile, Hobeika, Joëlle, Guisier, Florian, Chouaid, Christos
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7761573/
https://ncbi.nlm.nih.gov/pubmed/33276639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123608
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars